logo
Alnylam Receives European Commission Approval for AMVUTTRA ® (vutrisiran) for the Treatment of ATTR Amyloidosis with Cardiomyopathy

Alnylam Receives European Commission Approval for AMVUTTRA ® (vutrisiran) for the Treatment of ATTR Amyloidosis with Cardiomyopathy

Business Wire5 hours ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNA interference (RNAi) therapeutics company, today announced that the European Commission (EC) has granted approval for the treatment of wild-type or hereditary transthyretin amyloidosis in adult patients with cardiomyopathy (ATTR-CM) as an additional indication for its orphan RNAi therapeutic AMVUTTRA ® (vutrisiran). The approval broadens the indication for AMVUTTRA, which now becomes the first and only RNAi therapeutic approved by the EC for the treatment of the cardiomyopathy manifestations of ATTR amyloidosis and the polyneuropathy manifestations of hereditary transthyretin-mediated amyloidosis (hATTR) in adults.
Alnylam Receives European Commission Approval for AMVUTTRA® (vutrisiran) for the Treatment of ATTR Amyloidosis with Cardiomyopathy
Share
'Estimates show approximately 100,000 people are affected by ATTR amyloidosis across Europe, most with cardiomyopathy, so this approval marks a critical step toward addressing this underserved patient population,' said Pushkal Garg, M.D., Chief Medical Officer at Alnylam. 'AMVUTTRA is supported by a well-established efficacy and safety profile, with over 6,000 patient-years of global experience in the treatment of hATTR with polyneuropathy. By delivering rapid and sustained knockdown of TTR through convenient, quarterly dosing, it offers a clinically differentiated approach with the potential to transform outcomes for patients living with this debilitating and potentially fatal disease. We now look forward to securing access to AMVUTTRA for eligible patients across the EU as quickly as possible.'
The EC decision is based on positive results from the pivotal HELIOS-B Phase 3 study – a randomized, double-blind, placebo-controlled, multicenter, global trial that enrolled a diverse group of patients reflective of the contemporary ATTR-CM population, including those receiving substantial concurrent use of available standard-of-care therapies such as tafamidis and SGLT2 inhibitors. AMVUTTRA met all 10 pre-specified primary and secondary endpoints across both the overall and monotherapy populations. These included statistically significant reductions in all-cause mortality and recurrent cardiovascular events, as well as significant improvements in functional capacity (6-minute walk test), health status and quality of life (Kansas City Cardiomyopathy Questionnaire), and heart failure symptoms and severity (NYHA class). In the overall population, AMVUTTRA achieved a 28% reduction in the primary composite of all-cause mortality and recurrent cardiovascular events as compared to placebo. Mortality in this population was significantly reduced by 36% through 42 months in a pre-specified secondary endpoint analysis which included up to 36 months of the double-blind period plus six months of open-label extension. In HELIOS-B, rates of adverse events (AEs), serious AEs, severe AEs and AEs leading to study drug discontinuation were similar between the AMVUTTRA and placebo arms. Adverse drug reactions of AMVUTTRA include injection site reactions and increase in blood alkaline phosphatase and alanine transaminase. Detailed results from the HELIOS-B study were published in The New England Journal of Medicine. 1
'The HELIOS-B findings provide compelling evidence to support the use of vutrisiran as a first-line treatment option for patients with ATTR-CM,' said Marianna Fontana, M.D., Ph.D., HELIOS-B investigator, Professor of Cardiology, University College London, National Amyloidosis Center, Royal Free Hospital, London. 'As a physician, it is a privilege to see the true impact on patients in the clinic. The trial enrolled a broad population reflective of real-world clinical practice, and that's what makes the results so meaningful. This is a milestone for patients, who now have a new treatment option that has the potential to significantly improve outcomes of this disease.'
ATTR-CM is caused by the deposition of misfolded TTR fibrils, which drive progressive and irreversible cardiovascular damage and premature death. AMVUTTRA is an RNAi therapeutic that works upstream by delivering sustained knockdown of disease-causing TTR at its source. In the EU, it is administered as a subcutaneous injection once every three months, either by a healthcare professional, or self-administered by patients or their caregivers, offering flexibility in treatment delivery.
'Amyloidosis is a serious and progressive disease that significantly impacts not only patients' physical health, but also their quality of life and independence. I am thrilled by the news of a new therapy for people in the EU living with ATTR-CM who often face delayed diagnosis. Having a new treatment option available marks a welcome development for the amyloidosis community,' said Giovanni d'Alessio, President of the Amyloidosis Alliance.
In May 2025, the European Medicines Agency's Committee for Orphan Medicinal Products (COMP) adopted a positive opinion on the maintenance of the EU Orphan Designation for AMVUTTRA in ATTR amyloidosis.
AMVUTTRA was approved in March 2025 by the U.S. Food and Drug Administration (FDA) and the Brazilian Health Regulatory Agency (ANVISA) for the treatment of the cardiomyopathy of wild-type or hereditary ATTR amyloidosis in adults. Alnylam continues to pursue additional global submissions to bring vutrisiran to patients worldwide.
Indications
In the EU, AMVUTTRA ® (vutrisiran) is indicated for the treatment of:
hereditary transthyretin amyloidosis in adult patients with stage 1 or stage 2 polyneuropathy (hATTR-PN).
wild-type or hereditary transthyretin amyloidosis in adult patients with cardiomyopathy (ATTR-CM).
Important Safety Information
Reduced Serum Vitamin A Levels and Recommended Supplementation
Vutrisiran treatment leads to a decrease in serum vitamin A levels. Supplementation of approximately, but not exceeding, 2500 IU to 3000 IU vitamin A per day is advised for patients taking vutrisiran. Patients should be referred to an ophthalmologist if they develop ocular symptoms suggestive of vitamin A deficiency (e.g., night blindness).
Adverse Reactions
Commonly reported adverse reactions with vutrisiran were injection site reactions and increase in blood alkaline phosphatase and alanine transaminase.
For additional information about vutrisiran, please see the full Summary of Product Characteristics.
About AMVUTTRA ® (vutrisiran)
AMVUTTRA ® (vutrisiran) is an RNAi therapeutic that delivers rapid knockdown of variant and wild‑type transthyretin (TTR), addressing the underlying cause of transthyretin (ATTR) amyloidosis. Administered quarterly via subcutaneous injection, vutrisiran is approved and marketed in more than 15 countries for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR-PN) in adults. It is also approved in the U.S. and Brazil for the treatment of wild-type or hereditary ATTR amyloidosis in adult patients with cardiomyopathy (ATTR-CM). In the EU, AMVUTTRA is administered once every three months, either by a healthcare professional or through self-administration by patients or their caregivers.
About ATTR
Transthyretin amyloidosis (ATTR) is an underdiagnosed, rapidly progressive, debilitating and fatal disease caused by misfolded transthyretin (TTR) proteins, which accumulate as amyloid deposits in various parts of the body, including the nerves, heart and gastrointestinal tract. Patients may present with polyneuropathy, cardiomyopathy or both manifestations of disease. There are two different forms of ATTR – hereditary ATTR (hATTR), which is caused by a TTR gene variant and affects approximately 50,000 people worldwide, and wild-type ATTR (wtATTR), which occurs without a TTR gene variant and impacts an estimated 200,000-300,000 people worldwide. 2-5
About RNAi
RNAi (RNA interference) is a natural cellular process of gene silencing that represents one of the most promising and rapidly advancing frontiers in biology and drug development today. 6 Its discovery has been heralded as 'a major scientific breakthrough that happens once every decade or so,' and was recognized with the award of the 2006 Nobel Prize for Physiology or Medicine. 7 By harnessing the natural biological process of RNAi occurring in our cells, a new class of medicines known as RNAi therapeutics is now a reality. Small interfering RNA (siRNA), the molecules that mediate RNAi and comprise Alnylam's RNAi therapeutic platform, function upstream of today's medicines by potently silencing messenger RNA (mRNA) – the genetic precursors that encode for disease-causing or disease pathway proteins – thus preventing them from being made. 6 This is a revolutionary approach with the potential to transform the care of patients with genetic and other diseases.
About Alnylam Pharmaceuticals
Alnylam (Nasdaq: ALNY) has led the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare and prevalent diseases with unmet need. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach yielding transformative medicines. Since its founding in 2002, Alnylam has led the RNAi Revolution and continues to deliver on a bold vision to turn scientific possibility into reality. Alnylam has a deep pipeline of investigational medicines, including multiple product candidates that are in late-stage development. Alnylam is executing on its ' Alnylam P 5 x25 ' strategy to deliver transformative medicines in both rare and common diseases benefiting patients around the world through sustainable innovation and exceptional financial performance, resulting in a leading biotech profile. Alnylam is headquartered in Cambridge, MA.
Alnylam Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. All statements other than historical statements of fact regarding Alnylam's expectations, beliefs, goals, plans or prospects including, without limitation, Alnylam's expectations regarding the safety and efficacy of AMVUTTRA for the treatment of ATTR-CM; the potential for AMVUTTRA to be used as a first-line treatment for ATTR-CM; the potential for AMVUTTRA to address the underserved ATTR-CM patient population and to improve outcomes for ATTR-CM patients; and Alnylam's ability to secure access to AMVUTTRA for eligible patients across the EU and the timing of such access should be considered forward-looking statements. Actual results and future plans may differ materially from those indicated by these forward-looking statements as a result of various important risks, uncertainties and other factors, including, without limitation, risks and uncertainties relating to: Alnylam's ability to successfully execute on its ' Alnylam P 5 x25 ' strategy; Alnylam's ability to successfully demonstrate the efficacy and safety of its product candidates; the pre-clinical and clinical results for Alnylam's product candidates; actions or advice of regulatory agencies and Alnylam's ability to obtain regulatory approval for its product candidates, as well as favorable pricing and reimbursement; successfully launching, marketing and selling Alnylam's approved products globally; and any delays, interruptions or failures in the manufacture and supply of Alnylam's product candidates or its marketed products; as well as those risks more fully discussed in the 'Risk Factors' filed with Alnylam's 2024 Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC), as may be updated from time to time in Alnylam's subsequent Quarterly Reports on Form 10-Q and in its other SEC filings. In addition, any forward-looking statements represent Alnylam's views only as of today and should not be relied upon as representing its views as of any subsequent date. Alnylam explicitly disclaims any obligation, except to the extent required by law, to update any forward-looking statements.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Was Jim Cramer Right Choosing Constellation Energy (CEG) Over Vistra Last Year?
Was Jim Cramer Right Choosing Constellation Energy (CEG) Over Vistra Last Year?

Yahoo

time25 minutes ago

  • Yahoo

Was Jim Cramer Right Choosing Constellation Energy (CEG) Over Vistra Last Year?

We recently published a list of . In this article, we are going to take a look at where Constellation Energy Corporation (NASDAQ:CEG) stands against other stocks that Jim Cramer discusses. Cramer brought up Constellation Energy Corporation (NASDAQ:CEG) in the same segment as a key peer to Vistra. Back then, he explained why he still favored Constellation, highlighting its purer nuclear focus, longer-term stability, and his deeper familiarity with the company's management and performance history. Here are his remarks from back then: 'Right now, we're in the midst of an enormous AI infrastructure buildout… meaning tons and tons of data centers that practically devour electricity… and that's where the independent power producers come in—especially the ones that can provide clean energy like Vistra or Constellation Energy. […] A close up of a wind turbine producing electricity as the sun sets. Although CEG did not outperform Vistra, it's still up by 51.22%, making this a great call. Constellation Energy Corporation (NASDAQ:CEG) is a leading clean energy provider that generates electricity from nuclear, solar, wind, and hydro sources for residential and commercial customers. Cramer recently advised against owning energy stocks due to Microsoft's decision to close down some data centers. Here's what he said in April: 'Now, see, I never really, really care right now, honestly for the energy trade, because then Microsoft will say that it's closing a data center. No one will like the group. So let's stay away from the energy trade. It's too much second derivative, so to speak.' Overall, CEG ranks 2nd on our list of stocks that Jim Cramer discusses. While we acknowledge the potential of CEG as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Bridgewater Bank and Federal Home Loan Bank of Des Moines Award $800,000 to Minnesota Nonprofits Through Matching Grant Program
Bridgewater Bank and Federal Home Loan Bank of Des Moines Award $800,000 to Minnesota Nonprofits Through Matching Grant Program

Yahoo

time28 minutes ago

  • Yahoo

Bridgewater Bank and Federal Home Loan Bank of Des Moines Award $800,000 to Minnesota Nonprofits Through Matching Grant Program

ST. LOUIS PARK, Minn., June 09, 2025--(BUSINESS WIRE)--Bridgewater Bank, in partnership with the Federal Home Loan Bank of Des Moines (FHLB Des Moines), has awarded $800,000 to 23 local nonprofit organizations through the 2025 Member Impact Fund, a matching grant initiative focused on strengthening affordable housing and community development efforts. The Member Impact Fund provides members with up to $3 in matching funds for every $1 contributed to eligible nonprofits. Beyond its previously planned 2025 charitable giving, Bridgewater Bank committed an additional $100,000, resulting in a significantly larger pool of support for nonprofit partners serving Minnesota communities. "As a local bank and leader in the affordable housing space, we are thrilled to amplify our community impact through this meaningful collaboration with FHLB Des Moines," said Nick Place, Chief Banking Officer at Bridgewater Bank. "This program strengthens our ability to support some of the most impactful organizations in our state and bring transformational resources to the table." Confirmed grant recipients include: Minnesota Housing Partnership CommonBond Communities Habitat for Humanity of Minnesota Twin Cities Housing Alliance Bridging Trellis Rethos (Full recipient list available upon request) "Minnesota Housing Partnership is deeply grateful to Bridgewater Bank for their generous and strategic contribution to advancing our work. Across Minnesota, we need more homes to help our state thrive—and each of us has a role to play in making that happen. Our partnership with Bridgewater Bank reflects a shared commitment to creating the homes Minnesota needs," said Anne Mavity, Executive Director of Minnesota Housing Partnership. Since its founding in 2023, the Member Impact Fund has supported affordable housing and community development with nearly $70 million in grants awarded by FHLB Des Moines. "The Member Impact Fund continues to be a powerful resource in supporting our members as they expand access to affordable housing and drive community development," said Kris Williams, President and CEO of FHLB Des Moines. "It's inspiring to see the partnerships centered around improving local communities in such a variety of ways." Member FDIC | Equal Housing Lender About Bridgewater Bridgewater Bancshares, Inc. (Nasdaq: BWB) is a St. Louis Park, Minnesota-based financial holding company founded in 2005. Its banking subsidiary, Bridgewater Bank, is a premier, full-service bank dedicated to providing responsive support and simple solutions to businesses, entrepreneurs, and successful individuals across the Twin Cities. Bridgewater offers a comprehensive suite of products and services spanning deposits, lending, and treasury management solutions. Bridgewater has also received numerous awards for its banking services and esteemed corporate culture. With total assets of $5.1 billion and nine strategically located branches as of March 31, 2025, Bridgewater is one of the largest locally-led banks in Minnesota and is committed to being the finest entrepreneurial bank. For more information, please visit About FHLB Des Moines The Federal Home Loan Bank of Des Moines is deeply committed to strengthening communities, serving 13 states and three U.S Pacific territories as a member-owned cooperative. We work together with over 1,200 member institutions to support affordable housing, economic development and community improvement. FHLB Des Moines is one of 11 regional Banks that make up the Federal Home Loan Bank System. Members include community and commercial banks, credit unions, insurance companies, thrifts and community development financial institutions. FHLB Des Moines is wholly owned by its members and receives no taxpayer funding. For additional information about FHLB Des Moines, please visit View source version on Contacts Media Contacts:Jessica Stejskal | SVP Marketing | Bridgewater | 952.893.6860 Rachel Wegmann | Public Relations Manager | FHLB Des Moinesrwegmann@ | 515.412.2357 Investor Contact | Bridgewater Bank: Justin Horstman | VP Investor | 952.542.5169

AMD's Shopping Spree Continues. Is the AI Stock a Buy?
AMD's Shopping Spree Continues. Is the AI Stock a Buy?

Yahoo

time30 minutes ago

  • Yahoo

AMD's Shopping Spree Continues. Is the AI Stock a Buy?

AMD just acquired Brium, an AI software company. The move follows several acquisitions in AI, including ZT Systems. The stock is reasonably priced after falling sharply over the last year. 10 stocks we like better than Advanced Micro Devices › AMD (NASDAQ: AMD) might be the biggest sleeper stock in the artificial intelligence (AI) chip business right now. The stock is down nearly 50% from its peak last year. It seems investors got ahead of themselves in betting on AMD to break through in AI chips and challenge Nvidia. However, while the stock has tumbled, AMD's data center business is gaining traction. Revenue in the AI-focused segment jumped 57% in its first quarter to $3.7 billion, driven by growth in its EPYC central processing unit (CPU) and Instinct graphics processing unit (GPU) franchises. In addition to that momentum, AMD has also been making a number of moves to rearrange its portfolio to position it better for the AI era. In the first quarter, AMD acquired ZT Systems for $4.9 billion to help provide rack-scale solutions and high-performance systems, scaling up from its semiconductor business. After making that move, AMD turned around and said it would sell the server manufacturing business to Sanmina for $3 billion and continue to focus on design, rather than manufacturing. AMD is retaining ZT Systems' "rack-scale AI solutions design and customer enablement expertise." However, that's not the only deal AMD has made to advance its AI ambitions. It just announced the acquisition of Brium, a technology company that helps make AI software work across various hardware platforms. The move should help AMD better compete with Nvidia, as AI workloads are typically optimized for Nvidia's CUDA programming ecosystem. The deal was AMD's fourth AI acquisition in the last two years (the others being Silo AI, and Mipsology). Silo AI was the largest private AI lab in Europe before AMD acquired it for $665 million, giving the company a team of world-class AI scientists and engineers. an AI software company, gave AMD a similar boost in AI software for products like the Instinct data center GPUs, and Mipsology helped beef up AMD's inference software capabilities. None of these acquisitions have had a significant impact on AMD's share price, but combined, the moves show the company is clearly being aggressive with its AI strategy and that it understands the assignment. It needs to beef up its AI ecosystem to go beyond chips, which the ZT Systems deals help accomplish, and it needs to challenge the supremacy of CUDA or find a way around it. AMD has a similar programming software platform called ROCm, but it hasn't gained nearly as much adoption as CUDA. AMD's success in the future will be determined in large part by how it competes in AI and whether it can close the gap with Nvidia in programming software and other capabilities. The company is likely to continue making acquisitions. For a company with as much upside potential as AMD, the stock looks surprisingly affordable at a forward P/E of less than 30. In its first quarter, AMD reported revenue growth of 36% to $7.44 billion and a 55% increase in adjusted earnings per share to $0.96. Hyperscalers like Oracle and Google Cloud are expanding deployments of EPYC CPUs. AMD's client segment delivered strong growth in the quarter with revenue up 68% to $2.3 billion. For the second quarter, the company expects revenue growth of 27% to $7.4 billion, though that includes an $800 million impairment related to Chinese export restrictions. AMD isn't a sure thing in AI, but the company has a history of success under CEO Lisa Su, and the acquisitions are enhancing its position and improving its prospects. At the current valuation, AMD looks like a smart buy based on its current growth rate and its potential in the large and expanding AI market. Before you buy stock in Advanced Micro Devices, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Advanced Micro Devices wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $669,517!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $868,615!* Now, it's worth noting Stock Advisor's total average return is 792% — a market-crushing outperformance compared to 173% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 2, 2025 Jeremy Bowman has positions in Advanced Micro Devices and Nvidia. The Motley Fool has positions in and recommends Advanced Micro Devices, Nvidia, and Oracle. The Motley Fool has a disclosure policy. AMD's Shopping Spree Continues. Is the AI Stock a Buy? was originally published by The Motley Fool

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store